FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer
The FDA approved the first-in-class targeted therapy for metastatic pancreatic cancer, an oral small-molecule RAS inhibitor. This is the first time a RAS-targeted drug has been cleared for this indication, overcoming a protein previously deemed undruggable.
Pancreatic cancer is one of the most lethal malignancies, and the vast majority of cases harbor RAS mutations. This approval validates a long-sought approach to target KRAS and could pave the way for similar therapies across many other RAS-mutant cancers.
The approval was granted roughly one month after the FDA accepted the new drug application under the agency's CNPV pilot program, much faster than typical priority (8 months) or standard (12 months) review timelines. RAS mutations occur in over 90% of pancreatic ductal adenocarcinomas, and the drug belongs to the RAS(ON) multiselective inhibitor class.
hackernews · leopoldj · · Discussion · Single source
Background, discussion, and references
Background
RAS proteins are small GTPases that relay growth signals inside cells; activating mutations permanently switch them on and drive cancer. RAS mutations are found in 20–25% of all human tumors and up to 90% of pancreatic cancers. For decades, the protein was considered undruggable because its smooth surface offered no obvious pocket for a drug to bind. The new therapy works by binding to the active, GTP-bound form of RAS (RAS(ON)), simultaneously blocking multiple mutant and wild-type RAS proteins.
Discussion
Commenters shared deeply personal stories about family members with pancreatic cancer, expressing gratitude and wishing the drug had arrived sooner. One technical commenter highlighted the unusually fast FDA review—about one month from NDA acceptance to approval under the CNPV pilot program—and predicted this would be the first of many approvals for RAS-mutant cancers.
References
Tags
#FDA#pancreatic cancer#targeted therapy#RAS inhibitor#medical breakthrough